Information Provided By:
Fly News Breaks for September 20, 2018
ACAD
Sep 20, 2018 | 15:18 EDT
JMP Securities analyst Jason Butler reiterated a Market Outperform rating and $27 price target on Acadia Pharmaceuticals after the FDA reaffirmed its confidence in Nuplazid safety profile following completion of a comprehensive safety review. Butler sees this as an "important signal of confidence in the drug's safety profile" and sees this as a clearing event for the stock. He sees these catalysts driving the stock meaningfully higher in the coming months.
News For ACAD From the Last 2 Days
ACAD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.